AGAlexander Grabner

Alexander Grabner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Grabner has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Myles Wolf

    Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York-Presbyterian/Weill Cornell Medical Center, New York, New York

    6 shared publications
  • Christian Faul

    Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA

    4 shared publications
  • Christopher Yanucil

    Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA

    4 shared publications
  • Brian Czaya

    Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA

    3 shared publications
  • Christian Faul

    Section of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, USA

    3 shared publications
  • Michaela Alexandra Anna Fuchs

    Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA

    3 shared publications

Latest Publications

  • The authors reply

    by Michaela A.A. Fuchs, Myles Wolf, Alexander Grabner

  • Top Cited Papers
    Open Access

    Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease

    by Michaela A.A. Fuchs, Emily J. Burke, Nejla Latic, Susan L. Murray, Hanjun Li, Matthew A. Sparks, Dennis Abraham, Hengtao Zhang, Paul Rosenberg, Umber Saleem, et al.


  • Open Access

    Intestinal Cyp24a1 regulates vitamin D locally independent of systemic regulation by renal Cyp24a1 in mice

    by Michaela A.A. Fuchs, Alexander Grabner, Melody Shi, Susan L. Murray, Emily J. Burke, Nejla Latic, Venkataramana Thiriveedi, Jatin Roper, Shintaro Ide, Koki Abe, et al.

    Vitamin D regulates mineral homeostasis. The most biologically active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), is synthesized by CYP27B1 from 25-dihydroxyvitamin D (25D) and is inactivated by CYP24A1. Human monogenic diseases and genome-wide association studies support a critical role for CYP24A1 in regulation of mineral homeostasis, but little is known about its tissue-specific effects. Here, we describe the responses of mice with inducible global deletion, kidney-specific, and intestine-specific deletion of Cyp24a1 to dietary calcium challenge and chronic kidney disease (CKD). Global and kidney-specific Cyp24a1 deletion caused similar syndromes of systemic vitamin D intoxication: elevated circulating 1,25D, 25D, and fibroblast growth factor 23 (FGF23), activation of vitamin D target genes in the kidney and intestine, hypercalcemia, and suppressed parathyroid hormone (PTH). In contrast, mice with intestine-specific Cyp24a1 deletion demonstrated activation of vitamin D target genes exclusively in the intestine, despite no changes in systemic vitamin D levels. In response to a high calcium diet, PTH was suppressed, despite normal serum calcium. In mice with CKD, intestinal Cyp24a1 deletion decreased PTH and FGF23 without precipitating hypercalcemia. These results implicate kidney CYP24A1 in systemic vitamin D regulation while independent local effects of intestinal CYP24A1 could be targeted to treat secondary hyperparathyroidism in CKD.


  • Open Access

    Fibroblast Growth Factor (FGF) 23 and FGF Receptor 4 promote cardiac metabolic remodeling in chronic kidney disease

    by Alexander Grabner, Michaela Fuchs, Emily Burke, Nejla Latic, Susan Murray, Hanjun Li, Matthew Sparks, Dennis Abraham, Hengtao Zhang, Paul Rosenberg, et al.

    Chronic kidney disease (CKD) is a global health epidemic that significantly increases mortality due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiac injury in CKD. High serum levels of fibroblast growth factor (FGF) 23 in patients with CKD may contribute mechanistically to the pathogenesis of LVH by activating FGF receptor (FGFR) 4 signaling in cardiac myocytes. Mitochondrial dysfunction and cardiac metabolic remodeling are early features of cardiac injury that predate development of hypertrophy, but these mechanisms of disease have been insufficiently studied in models of CKD. Wild-type mice with CKD induced by adenine diet developed LVH that was preceded by morphological changes in mitochondrial structure and evidence of cardiac mitochondrial and metabolic dysfunction. In bioengineered cardio-bundles and neonatal rat ventricular myocytes grown in vitro, FGF23-mediated activation of FGFR4 caused mitochondrial dysfunction, characterized by increased mitochondrial respiration and increased glycolysis, that preceded the development of cellular hypertrophy. The cardiac metabolic changes and associated mitochondrial dysfunction in mice with CKD were prevented by global or cardiac-specific deletion of FGFR4. These findings indicate that metabolic remodeling and mitochondrial dysfunction are early cardiac complications of CKD that precede structural remodeling of the heart. Mechanistically, FGF23-mediated activation of FGFR4 causes mitochondrial dysfunction, suggesting that early pharmacologic inhibition of FGFR4 might serve as novel therapeutic intervention to prevent development of LVH and heart failure in patients with CKD.


  • Open Access

    Deletion of Cardiac Fgf23 Impairs Myocardial Energy Metabolism and Ameliorates Fibrosis in a Pressure Overload Model in Mice

    by Reinhold Erben, Nejla Latic, Na Sun, Achim Buck, Ana Zupcic, Martin Hofer, Wenhan Chang, Axel Walch, Alexander Grabner

    Left ventricular hypertrophy (LVH) is associated with increased cardiac expression of fibroblast growth factor (FGF23) in mice and men. To further elucidate the pathophysiological role of locally produced FGF23 in LVH, we specifically ablated Fgf23 in cardiomyocytes by crossing Fgf23fl/fl mice with MLCv2-Cre transgenic mice, and employed transverse aortic constriction (TAC) to induce LVH by chronic pressure overload. The TAC-induced ~25-fold increase in cardiac Fgf23 mRNA expression was blunted in cardiomyocyte-specific Fgf23 knock-out (Fgf23CKO) mice. Serum Fgf23 levels were equally increased in all genotypes after TAC, suggesting that cardiac-derived Fgf23 does not contribute to the TAC-induced rise in circulating Fgf23. Heart-to-body weight ratio, cardiomyocyte size, and molecular hypertrophy markers were similarly increased in all TAC groups, showing that LVH developed inde-pendently of cardiac Fgf23. However, Fgf23CKO TAC mice showed reduced blood pressure upstream of the aortic constriction site, more pronounced eccentric hypertrophy, and a distinct reduction of cardiac fibrosis, relative to Fgf23fl/fl TAC controls. Spatial metabolomics using mass spectrometry imaging in heart cryosections revealed that lack of local Fgf23 secretion reduced intracellular glucose abundance and impaired cardiac energy metabolism. Conversely, treatment of cultured cardiomyocytes with recombinant FGF23 stimulated the abundance of intracellular glucose as evidenced by mass spectrometry imaging. Collectively, our data uncover a novel function of cardiomyocyte-derived Fgf23 as modulator of energy metabolism and of cardiac fibrosis in LVH.

  • Top Cited Papers

    FGF23 and klotho at the intersection of kidney and cardiovascular disease

    by Daniel Edmonston, Alexander Grabner, Myles Wolf

    Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral homeostasis, amplify traditional cardiovascular risk factors. Fibroblast growth factor 23 (FGF23) regulates mineral homeostasis by activating complexes of FGF receptors and transmembrane klotho co-receptors. A soluble form of klotho also acts as a ‘portable’ FGF23 co-receptor in tissues that do not express klotho. In progressive CKD, rising circulating FGF23 levels in combination with decreasing kidney expression of klotho results in klotho-independent effects of FGF23 on the heart that promote left ventricular hypertrophy, heart failure, atrial fibrillation and death. Emerging data suggest that soluble klotho might mitigate some of these effects via several candidate mechanisms. More research is needed to investigate FGF23 excess and klotho deficiency in specific cardiovascular complications of CKD, but the pathophysiological primacy of FGF23 excess versus klotho deficiency might never be precisely resolved, given the entangled feedback loops that they share. Therefore, randomized trials should prioritize clinical practicality over scientific certainty by targeting disordered mineral homeostasis holistically in an effort to improve cardiovascular outcomes in patients with CKD.


  • Open Access

    Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease

    by Christopher Yanucil, Dominik Kentrup, Isaac Campos, Brian Czaya, Kylie Heitman, David Westbrook, Gunars Osis, Alexander Grabner, Adam R. Wende, Julian Vallejo, et al.


  • Open Access

    C4d Deposition after Allogeneic Renal Transplantation in Rats Is Involved in Initial Apoptotic Cell Clearance

    by Stefan Reuter, Dominik Kentrup, Alexander Grabner, Gabriele Köhler, Konrad Buscher, Bayram Edemir

    In the context of transplantation, complement activation is associated with poor prognosis and outcome. While complement activation in antibody-mediated rejection is well-known, less is known about complement activation in acute T cell-mediated rejection (TCMR). There is increasing evidence that complement contributes to the clearance of apoptotic debris and tissue repair. In this regard, we have analysed published human kidney biopsy transcriptome data clearly showing upregulated expression of complement factors in TCMR. To clarify whether and how the complement system is activated early during acute TCMR, experimental syngeneic and allogeneic renal transplantations were performed. Using an allogeneic rat renal transplant model, we also observed upregulation of complement factors in TCMR in contrast to healthy kidneys and isograft controls. While staining for C4d was positive, staining with a C3d antibody showed no C3d deposition. FACS analysis of blood showed the absence of alloantibodies that could have explained the C4d deposition. Gene expression pathway analysis showed upregulation of pro-apoptotic factors in TCMR, and apoptotic endothelial cells were detected by ultrastructural analysis. Monocytes/macrophages were found to bind to and phagocytise these apoptotic cells. Therefore, we conclude that early C4d deposition in TCMR may be relevant to the clearance of apoptotic cells.


  • Open Access

    Importance of Extra-Renal CYP24A1 Expression for Maintaining Mineral Homeostasis

    by Melody Shi, Alexander Grabner, Myles Wolf

    Calcium homeostasis involves a complex interplay between kidneys, parathyroid glands, intestine and bone. Specifically, 1,25(OH)2D3 is a key calciotropic hormone which stimulates intestinal calcium absorption. A growing body of evidence suggests that circulating levels of 1,25(OH)2D3 depend not only on its synthesis under the action of PTH in the kidneys, but also its catabolism by 24-hydroxylase, herein referred to as CYP24A1. The clinical importance of CYP24A1 has been demonstrated by human loss-of-function mutations, which lead to severe hypercalcemia due to exaggerated levels of 1,25(OH)2D3. Despite its growing importance, little is known about its tissue-specific contributions to normal vitamin D metabolism. To explore the physiology of CYP24A1 and delineate renal-specific effects of CYP24A1 in calcium metabolism, we generated a mouse with constitutive kidney-specific deletion of Cyp24a1 (Six2Cre-Cyp24flox). Six2 marks the nephron progenitor population throughout nephrogenesis. We hypothesized that hypercalcemia as seen in CYP24A1 inactivating mutations is related to lack of both renal and extrarenal expression, and that renal deletion does not lead to severe hypercalcemia. To confirm Cyp24a1 deletion, we measured mRNA expression in the kidney using qPCR and RNA in situ hybridization. All mice were fed a standard commercial rodent diet and followed longitudinally for five months with interval calcium measurements. At time of termination, serum PTH levels were measured along with vitamin D-dependent calcium transporters as a functional measure of 1,25(OH)2D3 action. Cyp24a1 expression was significantly knocked down in total kidneys from Six2Cre-Cyp24flox mice as compared to intestinal expression suggesting successful gene deletion. Compared to age-matched wildtype controls, Six2Cre-Cyp24flox mice were mildly but persistently hypercalcemic (diff between means= 0.46 mg/dL, p-value: 0.03, n=8 per group). As expected, 1,25D-dependent calcium transporters in the kidney (Calb1, Trpv5, Slc8a1, Atp2b1) and intestine (Trpv6, s100g) were all increased, consistent with increased systemic 1,25(OH)2D3 activity. PTH levels were appropriately suppressed in the Six2Cre-Cyp24flox mice (diff between means=83 pg/mL, p-value 0.2, n=9 control, n=3 exp) as were renal cyp27b1 mRNA expression. These data suggest that renal CYP24A1 is important for systemic 1,25(OH)2D3 regulation, but the lack of severe hypercalcemia supports critical contributions of extra-renal CYP24A1.


  • Kidney to bone via bedside to bench…and back?

    by Alexander Grabner, Myles Wolf

    The rapid rise in circulating fibroblast growth factor 23 (FGF23) associated with kidney injury results in calcitriol deficiency, altered calcium homeostasis, and secondary hyperparathyroidism, and may contribute to cardiovascular complications and death. However, the mechanisms of increased FGF23 in states of kidney injury remain unclear. In this issue of the JCI, Simic et al. screened plasma taken from the renal vein of patients undergoing cardiac catheterization and identified glycerol-3-phosphate (G-3-P) as the most significant correlate of simultaneous arterial FGF23 levels. When G-3-P was administered to mice, FGF23 production increased in bone. In a series of elegant mouse studies, the authors discovered a pathway linking increased G-3-P to increased FGF23 via increases in lysophosphatidic acid (LPA), which activates the LPA receptor 1 in FGF23-secreting cells in the bone and bone marrow. Although the authors present human data that broadly support the results from the mouse models, further research is needed to determine whether targeting the G-3-P/FGF23 pathway has the potential to modify FGF23-related complications in the clinic.